利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

45 条记录 (耗时 0.032 秒)

    METHODS OF IDENTIFYING AND USING MDM2 INHIBITORS
    22.
    发明申请
    METHODS OF IDENTIFYING AND USING MDM2 INHIBITORS 有权
    鉴定和使用MDM2抑制剂的方法

    公开(公告)号：US20140336202A1

    公开(公告)日：2014-11-13

    申请号：US14363346

    申请日：2012-12-07

    申请人： DUKE UNIVERSITY

    发明人： Sally Kornbluth ,  Manabu Kurokawa ,  Neil Spector ,  Mark Dewhirst

    IPC分类号： A61K31/517 ,  A61K31/404 ,  G01N33/50 ,  A61K31/496

    CPC分类号： A61K31/517 ,  A61K31/404 ,  A61K31/407 ,  A61K31/496 ,  A61K39/39558 ,  A61K45/06 ,  C07K16/32 ,  C12N15/1135 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/531 ,  C12Y603/02 ,  G01N33/5011 ,  G01N2800/52 ,  A61K2300/00

    摘要： Methods of treating subjects with cancer and screening for MDM2 inhibitors that may be effective cancer therapeutics are provided herein. The cancers that may be treated using MDM2 inhibitors using the methods described herein include those that are or may become resistant to treatment with tyrosine kinase inhibitors. Methods of treating subjects with cancers that have, or develop in response to treatment with tyrosine kinase inhibitors, elevated levels of MDM2, Mcl-1 or PP5 or decreased levels of Huwe1 or CAS using MDM2 inhibitors are provided herein. The MDM2 inhibitors may be effective at treating these cancers alone or in combination with a tyrosine kinase inhibitor regardless of p53 status (mutant or wild-type) of the cancer.

    摘要翻译： 本文提供了治疗患有癌症的受试者和筛选可能是有效的癌症治疗剂的MDM2抑制剂的方法。 可以使用本文所述方法使用MDM2抑制剂治疗的癌症包括对酪氨酸激酶抑制剂进行治疗或可能变得耐药的癌症。 本文提供了治疗患有癌症受试者的方法，该癌症具有或响应于酪氨酸激酶抑制剂治疗而发展，MDM2，Mcl-1或PP5水平升高或使用MDM2抑制剂降低Huwe1或CAS的水平。 MDM2抑制剂可以有效地单独或与酪氨酸激酶抑制剂组合治疗这些癌症，而不管癌症的p53状态（突变体或野生型）如何。

    Combination anti-HIV vectors, targeting vectors, and methods of use
    23.
    发明授权
    Combination anti-HIV vectors, targeting vectors, and methods of use 有权
    组合抗HIV载体，靶向载体和使用方法

    公开(公告)号：US08728458B2

    公开(公告)日：2014-05-20

    申请号：US13266236

    申请日：2010-04-29

    申请人： Joseph Anderson ,  Gerhard Bauer ,  Jan A. Nolta

    发明人： Joseph Anderson ,  Gerhard Bauer ,  Jan A. Nolta

    IPC分类号： A61K48/00

    CPC分类号： A61K48/0066 ,  A61K31/7105 ,  A61K38/53 ,  C07K14/7158 ,  C12N7/00 ,  C12N15/1138 ,  C12N15/86 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/531 ,  C12N2320/31 ,  C12N2320/32 ,  C12N2740/16011 ,  C12N2740/16043 ,  C12N2740/16051 ,  C12Y603/02

    摘要： Recombinant lentiviral vectors containing at least: a lentiviral backbone comprising essential lentiviral sequences for integration into a target cell genome; a nucleic acid encoding a CCR5 RNAi; and an expression control element that regulates expression of the nucleic acid encoding the CCR5 RNAi element, are provided by this invention. In an alternative aspect, the vector also contains polynucleotides encoding TRIM5 alpha and HIV TAR decoy sequences along with gene expression regulation elements such as promoters operatively linked to the polynucleotides. The vectors are combined with packaging plasmid and envelope plasmids and optionally conjugated to cell-specific targeting antibodies. Diagnostic and therapeutic methods for using the compositions are further provided herein.

    摘要翻译： 含有至少包含慢病毒骨架的重组慢病毒载体，其包含用于整合入靶细胞基因组的必需慢病毒序列; 编码CCR5 RNAi的核酸; 以及调节编码CCR5 RNAi元件的核酸表达的表达控制元件由本发明提供。 在另一方面，载体还含有编码TRIM5α和HIV TAR诱饵序列的多核苷酸以及基因表达调控元件，例如与多核苷酸可操作连接的启动子。 将载体与包装质粒和包膜质粒组合，并任选地与细胞特异性靶向抗体缀合。 本文进一步提供了使用组合物的诊断和治疗方法。

    Generation of acyl amino acids
    24.
    发明授权
    Generation of acyl amino acids 有权

    公开(公告)号：US12031167B2

    公开(公告)日：2024-07-09

    申请号：US17481290

    申请日：2021-09-21

    申请人： Modular Genetics, Inc.

    发明人： Kevin A. Jarrell ,  Gabriel O. Reznik ,  Prashanth Vishwanath ,  Michelle Pynn

    IPC分类号： C12N9/80 ,  A01N37/36 ,  C07C235/06 ,  C12N9/00 ,  C12P13/02

    CPC分类号： C12P13/02 ,  A01N37/36 ,  C07C235/06 ,  C12N9/80 ,  C12N9/93 ,  C12Y603/02

    摘要： In certain embodiments, the present invention comprises compositions and methods useful in the generation of acyl amino acids. In certain embodiments, the present invention provides an engineered polypeptide comprising a peptide synthetase domain; in some such embodiments, the engineered polypeptide comprises only a single peptide synthetase domain. In some embodiments, the present invention provides an engineered peptide synthetase that is substantially free of a thioesterase domain, and/or a reductase domain. In certain embodiments, the present invention provides an acyl amino acid composition comprising a plurality of different forms of an acyl amino acid. In some such compositions, substantially all of the acyl amino acids within the composition contain the same amino acid moiety and differ with respect to acyl moiety. We also described populations where the fatty acid is for example 95% one length (C14, myristic).

    INFLAMMATION-ENABLING POLYPEPTIDES AND USES THEREOF
    28.
    发明申请
    INFLAMMATION-ENABLING POLYPEPTIDES AND USES THEREOF 审中-公开
    炎症多肽的使用及其用途

    公开(公告)号：US20170072071A1

    公开(公告)日：2017-03-16

    申请号：US15281666

    申请日：2016-09-30

    申请人： THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY

    发明人： Philippe Gros

    IPC分类号： A61K49/00 ,  C12Q1/68 ,  C12N9/48

    CPC分类号： A61K49/0008 ,  C12N9/485 ,  C12N9/93 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Y304/19012 ,  C12Y603/02

    摘要： This present technology relates to the use of inflammation-enabling polypeptides (or their coding sequences) to screen for agents useful for the prevention, treatment and/or alleviations of symptoms associated with an inflammatory disorder, to identify individuals susceptible of developing an exacerbated inflammatory response as well as to determine if a therapeutic regimen is capable of preventing, treating or alleviating the symptoms associated to an inflammatory disorder in an individual. The present technology also provides methods for preventing, treating and/or alleviating the symptoms associated to an inflammatory condition based on the inhibition of expression or activity of the inflammation-enabling targets.

    摘要翻译： 本技术涉及使用炎症使能多肽（或其编码序列）筛选可用于预防，治疗和/或减轻与炎性病症相关的症状的药剂，以鉴定易于发展为恶化的炎症反应的个体 以及确定治疗方案是否能够预防，治疗或减轻与个体中炎症性疾病相关的症状。 本技术还提供了用于基于对炎症使能靶标的表达或活性的抑制来预防，治疗和/或缓解与炎性病症相关的症状的方法。